Previous 10 | Next 10 |
Prothena to receive $80 million from Bristol Myers Squibb for exclusive US license to PRX005; Next option for worldwide rights following completion of Phase 1 PRX005 is an investigational best-in-class anti-tau antibody targeting the microtubule binding region of tau for the treatment...
Gainers: Midatech Pharma (MTP) +33%.Cellect Biotechnology (APOP) +31%.iSun (ISUN) +23%.AGM Group (AGMH) +23%.Synaptogenix (SNPX) +21%9F (JFU) +18%.Capricor Therapeutics (CAPR) +15%.Clearside Biomedical (CLSD) +14%.Rezolute (RZLT) +14%.China Xiangtai Food (PLIN) +13%.Losers: ...
Gainers: Midatech Pharma (MTP) +37%, Cellect Biotechnology (APOP) +30%, Synaptogenix (SNPX) +24%, Clearside Biomedical (CLSD) +16%, Tiziana Life Sciences (TLSA) +16%.Losers: CureVac (CVAC) -44%, Novan (NOVN) -19%, Prothena (PRTA) -14...
PM Images/DigitalVision via Getty Images The shares of Alzheimer’s drug developer, Prothena Corporation ([[PRTA]] +4.2%) have reached the highest level since November 2017 driven by the optimism generated by the FDA decision to approve, Aduhelm, Biogen’s treatment for the m...
The U.S. Food and Drug Administration (FDA) granted accelerated approval to Biogen 's (NASDAQ: BIIB) Alzheimer's disease drug Aduhelm (aducanumab) on Monday . This news caused shares of the biotech to soar 44.9% this week as of the market close on Thursday. Biogen wasn't the...
DUBLIN, Ireland, June 10, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will part...
Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector. The lower bar set for approval poses risk for Biogen in the out years. ...
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to invest in multiple biotech companies via one vehicle. The life science sector certainly holds a risk factor, and ETFs are a good wa...
Photo by PM Images/DigitalVision via Getty Images After the FDA approval for Biogen’s Alzheimer’s therapy, Aduhelm yesterday, Oppenheimer has increased the price target for Prothena ([[PRTA]] -5.5%) by a fifth to $54.00 per share to indicate an upside of ~45.0%. The ...
Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment. Oncology companies get ready to present new data at the largest US oncology conference with potential fo...
News, Short Squeeze, Breakout and More Instantly...
Prothena Corporation plc Company Name:
PRTA Stock Symbol:
NASDAQ Market:
Prothena Corporation plc Website:
2024-07-03 23:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-02 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will initiate a Phase 1 clinical trial for PRX019 in 2024 Prothena Corporation plc (NASDAQ:PRTA),...